Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia

American Journal of Hematology

Volumn 83, Issue 3, 2008, Pages 185-188

  Zhang, Wang Gang ^a   Wang, Fang Xia ^a   Chen, Yin Xia ^a   Cao, Xin Mei ^a   He, Ai Li ^a   Liu, Jie ^a   Ma, Xiao Rong ^a   Zhao, Wan Hong ^a   Liu, Su Hu ^a   Wang, Jian Li ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; HOMOHARRINGTONINE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; CONTINUOUS INFUSION; CYTOGENETICS; DRUG CYTOTOXICITY; FEMALE; FOLLOW UP; HUMAN; INFECTION; LEUKEMIA CELL; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER DYSFUNCTION; LOW DRUG DOSE; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PILOT STUDY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE I AS TOPIC; CYTARABINE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HARRINGTONINES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEUTROPENIA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 39749118640     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20903     Document Type: Article

References (34)

1. Faderl S, Gandhi V, O'Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005;105:940-947.
2. Gert JO, Wilfried JG, Pieter S, et al. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. Blood 2004;103:2908-2913.
3. Walter F, Hubert S, Hartmut D, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005;105:986-993.
4. Graf M, Hecht K, Reif S, Pelka-Fleischer R, Pfister K, Schmetzer H. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): Implications for future therapeutical strategies. Eur J Haematol 2003;72:89-106.
5. Bhalla K, Birkhofer M, Arlin Z, Grant S, Lutzky J, Graham G. Effect of recombinant GM-CSF on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells. Leukemia 1988;2:810-813.
6. Lista P, Porcu P, Avanzi GC, Pegoraro L. Interleukin 3 enhances the cytotoxic activity of 1-D-arabinofuranosylcytosine (ara-C) on acute myeloblasts leukaemia (AML) cells. Br J Haematol 1988;70:121-123.
7. Te Boekhorst PA, Löwenberg B, Vlastuin M, Sonneveld P. Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation. Leukemia 1993;7:1191-1198.
8. Te Boekhorst PA, Löwenberg B, Sonneveld P. Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: Effects in untreated and relapsed or primary refractory acute myeloid leukemia cells. Leukemia 1994;8:1480-1486.
9. Yamada K, Furusawa S, Saito K, et al. Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoslde and aclarubicin for previously treated acute myelogenous leukemia: A pilot study. Leukemia 1995;9:10-14.
10. Bai A, Kojima H, Hori M, et al. Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells. Exp Hematol 1999;27:259-265.
11. Takemura Y, Ohnuma T, Chou TC, Okano T, Holland JF. Biologic and pharmacologic effects of harringtonine on human leukemia-lymphoma cells. Cancer Chemother Pharmacol 1985;14:206-210.
12. Zhou JY, Chen DL, Shen ZS, Koeffler HP. Effect of homoharringtonine on proliferation and differentiation of human leukemic cells in vitro. Cancer Res 1990;50:2031-2035.
13. Wen-Yuan M, Mao-Fang L. Induction of apoptosis by homoharringtonine in G1 phase human chronic myeloid leukemic cells. Chin Med J 2005;118:487-492.
14. Mao YQ, Li XR, Lei S. Effect of several anti-tumor drugs on apoptosis induction in Jurkat cell line. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2006;14:681-685.
15. Ye XJ, Lin MF. Homoharringtonine induces apoptosis of endothlium and down-regulates VEGF expression of K562 cells. J Zhejiang Univ Sci 2004;5:230-234.
16. Smith CR Jr, Powell RG, Mikolajczak KL. The genus Cephalotaxus: source of homoharringtonine and related anticancer alkaloids. Cancer Treat Rep 1976;60:1157-1170.
17. Cephalotaxus Research Coordinating Group. Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment. Chin Med J 1976;2:263-272.
18. Kantarjian HM, Keating MJ, Walters RS, Koller CA, McCredie KB, Freireich EJ. Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia. Cancer 1989;63:813-817.
19. Feldman E, Arlin Z, Ahmed T, et al. Homoharringtonine is safe and effective for patients with acute myelogenous leukemia. Leukemia 1992;6:1185-1188.
20. O'Brien S, Kantarjian H, Keating M, et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 1995;86:3322-3326.
21. Levv V, Zohar S, Bardin C, et al. A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukemia. Br J Cancer 2006;95:253-259.
22. Bell BA, Chang MN, Weinstein HJ. A phase II study of homoharringtonine for the treatment of children with refractory or recurrent acute myelogenous leukemia: A pediatric oncology group study. Med Pediatr Oncol 2001;37:103-107.
23. Fanucchi MP, Kong XR, Chou TC. Hexamethylene bisacetamide(HMBA) does not enhance the cytotoxic effects of adriamycin (ADR), 1,β-D- arabinofuranosylcytosine (ARA-C) and harringtonine (HT) in HL-60 cells. Proc Am Assoc Cancer Res 1986;27:376 (abstract 1492).
24. Feldman E, Arlin Z, Ahmed T, et al. Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia. Leukemia 1992;6:1189-1191.
25. Huang MT. Harringtonine, an inhibitor of initiation of protein biosynthesis. Mol Pharmacol 1975;11:511-519.
26. Fresno M, Jimenez A, Vazqueq D. Inhibition of translation in eukaryotic systems by harringtonine. Eur J Biochem 1977;72:323-330.
27. Cai Z, Bao HY, Lin MF. Correlation between survivin mRNA expression and homoharringtonine induced apoptosis of malignant hematopoietic cells. Chin Med J (Engl) 2005;118:548-554.
28. Wang H, Guo Z, Ji S. Homoharringtonine induces apoptosis of K562 cells through inhibition of P210 (bcr/abl). Zhongguo Shi Yan Xue Ye Xue Za Zhi 2000;8:287-289.
29. Xie WZ, Lin MF, Huang H, Cai Z. Homoharringtonine-induced apoptosis of human leukemia HL-60 cells is associated with down-regulation of telomerase. Am J Chin Med 2006;34:233-244.
30. Tang R, Faussat AM, Majdak P, et al. Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol Cancer Ther 2006;5:723-731.
31. Lowenberg B, van Putten W, Theobald M, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003;349:743-752.
32. Legha SS, Keating M, Picket S, Ajani JA, Ewer M, Bodey GP. Phase I clinical investigation of homoharringtonine. Cancer Treat Rep 1984;68:1085-1091.
33. Warrell RP Jr, Coonley CJ, Gee TS. Homoharringtonine: An effective new drug for remission induction in refractory non-lymphoblastic leukemia. J Clin Oncol 1985;3:617-621.
34. ISCN (International System for Human Cytogenetic Nomenclature). Guidelines for cancer cytogenetics. In: Mitelman F, editor. Supplement to an International System for Human Cytogenetic Nomenclature. Basel: Karger; 1991. pp 1-53.